Literature DB >> 31078721

Circulating retinol-binding protein 4 is associated with the development and regression of non-alcoholic fatty liver disease.

X Wang1, X Chen1, H Zhang1, J Pang1, J Lin2, X Xu3, L Yang4, J Ma1, W Ling5, Y Chen6.   

Abstract

AIM: Retinol-binding protein 4 (RBP4), primarily secreted by liver and adipose tissue, has been linked with non-alcoholic fatty liver disease (NAFLD). However, investigations on the relationships between RBP4 and NAFLD have produced inconsistent results. Therefore, the association between serum RBP4 levels and the development or regression of NAFLD was prospectively investigated.
METHODS: A total of 3389 Chinese adults, aged 40-75 years and followed-up for 3.09 years, were included and analyzed in the study. NAFLD was diagnosed by abdominal ultrasonography. Serum RBP4 levels were measured, and their relationship to NAFLD development and regression assessed.
RESULTS: Of the 1318 participants without NAFLD at baseline, 410 developed NAFLD after follow-up. Baseline RBP4 was positively associated with incident NAFLD: the fully adjusted odds ratio (OR) was 2.01 with a 95% confidence interval (CI) of 1.33-3.04 (P = 0.003 for trend). After follow-up, a significant increase in RBP4 levels was observed in participants who developed NAFLD. On the other hand, in 1382 subjects diagnosed with NAFLD at baseline, 339 experienced NAFLD regression after follow-up. Thus, baseline RBP4 was inversely associated with NAFLD regression: the fully adjusted OR was 0.52 with a 95% CI of 0.34-0.80 (P < 0.001 for trend). A significant decrease in RBP4 after follow-up was also noted in participants with NAFLD regression.
CONCLUSION: Serum RBP4 concentrations are associated with the development and regression of NAFLD, making them a potential novel preventative and therapeutic target in NAFLD management.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Adipokine; Fatty liver disease; Longitudinal study

Mesh:

Substances:

Year:  2019        PMID: 31078721     DOI: 10.1016/j.diabet.2019.04.009

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  10 in total

Review 1.  Understanding the Role of Metabolic Syndrome as a Risk Factor for Hepatocellular Carcinoma.

Authors:  Norberto C Chavez-Tapia; Sofía Murúa-Beltrán Gall; Ana Luisa Ordoñez-Vázquez; Natalia Nuño-Lambarri; Paulina Vidal-Cevallos; Misael Uribe
Journal:  J Hepatocell Carcinoma       Date:  2022-07-05

Review 2.  NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook.

Authors:  Alberto Nascè; Karim Gariani; François R Jornayvaz; Ildiko Szanto
Journal:  Antioxidants (Basel)       Date:  2022-06-09

Review 3.  Interplay of retinol binding protein 4 with obesity and associated chronic alterations (Review).

Authors:  Yaccil Adilene Flores-Cortez; Martha I Barragán-Bonilla; Juan M Mendoza-Bello; Cecilia González-Calixto; Eugenia Flores-Alfaro; Mónica Espinoza-Rojo
Journal:  Mol Med Rep       Date:  2022-06-03       Impact factor: 3.423

Review 4.  Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.

Authors:  Hyunmi Kim; Da Som Lee; Tae Hyeon An; Hyun-Ju Park; Won Kon Kim; Kwang-Hee Bae; Kyoung-Jin Oh
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 5.  Organ-organ communication: The liver's perspective.

Authors:  Fei Wang; Kwok-Fai So; Jia Xiao; Hua Wang
Journal:  Theranostics       Date:  2021-01-16       Impact factor: 11.556

6.  Study on the correlation between urinary retinol-binding protein and nonalcoholic fatty liver disease.

Authors:  Chuang Li; Weiwei Kong; Lixia Kang; Tiehan Zhang; Weiqun Zhang; Weidong Wang
Journal:  J Med Biochem       Date:  2021-01-26       Impact factor: 3.402

7.  Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study.

Authors:  Xia Fang; Hongya Wang; Ting Ye; Xiaolan Fu; Xiaozhen Tan; Yan Zeng; Jiahao Fan; Yong Xu
Journal:  Lipids Health Dis       Date:  2021-08-30       Impact factor: 3.876

Review 8.  Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?

Authors:  Vera Francisco; Maria Jesus Sanz; José T Real; Patrice Marques; Maurizio Capuozzo; Djedjiga Ait Eldjoudi; Oreste Gualillo
Journal:  Biology (Basel)       Date:  2022-08-19

Review 9.  Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis.

Authors:  Bing Yang; Liqing Lu; Dongmei Zhou; Wei Fan; Lucía Barbier-Torres; Justin Steggerda; Heping Yang; Xi Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-30       Impact factor: 6.055

10.  ERα-Dependent Regulation of Adropin Predicts Sex Differences in Liver Homeostasis during High-Fat Diet.

Authors:  Clara Meda; Arianna Dolce; Elisabetta Vegeto; Adriana Maggi; Sara Della Torre
Journal:  Nutrients       Date:  2022-08-10       Impact factor: 6.706

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.